Analytical Data
-
Gene name
DOCK2
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92608
-
Expression Region
Ile390~Glu635
-
Molecular Weight
32kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DOCK2 (Dedicator of Cytokinesis 2) is a member of the DOCK family of proteins, which are known for their role as guanine nucleotide exchange factors (GEFs) that activate small GTPases. This signaling pathway is crucial for various cellular processes, including cell migration, adhesion, and the immune response. DOCK2 is predominantly expressed in hematopoietic cells and has gained extensive interest due to its involvement in lymphocyte function and development. Research has demonstrated that DOCK2 facilitates the activation of Rho GTPases, which are essential for cytoskeleton reorganization and cellular motility. Mutations or dysregulation of DOCK2 have been implicated in various immunological disorders and cancers, highlighting its potential as a therapeutic target. The study of recombinant DOCK2 proteins not only aids in understanding its structure-function relationship but also illuminates the molecular mechanisms underlying its role in signaling pathways. Researchers utilize recombinant protein techniques to produce DOCK2 for detailed biochemical and biophysical studies, enabling the exploration of its interactions with other cellular components. This research ultimately aims to delineate the functional roles of DOCK2 in health and disease, paving the way for the development of novel therapeutic strategies targeting this protein for immunological and oncological conditions.
